^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins

Published date:
08/19/2021
Excerpt:
GZ17-6.02 interacted with the thymidylate synthase inhibitor pemetrexed to kill NSCLC cells expressing mutant ERBB1 proteins or mutant RAS proteins or cells that were resistant to EGFR inhibitors....GZ17-6.02 and pemetrexed interact to alter cell signaling, increase autophagosome formation, and kill via toxic autophagy A549 NSCLC cells that express a mutant K-RAS protein.
Secondary therapy:
pemetrexed
DOI:
https://doi.org/10.3389/fonc.2021.711043